8hon MSN
BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch
Q3 2025 Management View Jay Short, Co-Founder, CEO & Chairman, emphasized that BioAtla is "currently in advanced stages to ...
Putting the evidence together, it becomes clear that regulation and business models are late-stage refinements, not root ...
Thursday, November 13, 2025 at 11:00 a.m. ET. CALL PARTICIPANTS. President and Chief Executive Officer — Marty Neese; Chief ...
The battle against HIV in sub-Saharan Africa has always been as much about systems and science as about the virus itself. Antiretroviral therapy has turned what was once a death sentence into a ...
R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first frontline immunotherapy for advan ...
Private capital is expected to play a critical role in mobilising $1.3tn of finance needed to fight climate change. AI, if ...
The prevailing assumption is that executives only need high-level briefings, not practical AI training. That's wrong.
Shift verification effort from a single, time-consuming flat run to a more efficient, distributed, and scalable process.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results